Question Title

* 1. I am:

Epidemiology

Question Title

* 2. Which of the following do you consider to be the most problematic fungal pathogen at your institution?

Question Title

* 3. In your practice, how often do you encounter Candida isolates that exhibit resistance to azole therapy?

Question Title

* 4. At your institution, first-line treatment for a patient with neutropenic fever (>72 hours) and with a suspected Candida infection is:

Diagnostics

Question Title

* 5. A diagnostic test to differentiate among Candida species from blood culture is:

Question Title

* 6. At your institution, when an IFI is suspected, how much time typically passes before antifungal treatment is initiated?

Question Title

* 7. When invasive candidiasis is confirmed, how often do you request for susceptibility testing?

Prophylaxis

Question Title

* 8. How often do you utilize IDSA guidelines when selecting antifungal prophylaxis for at-risk patients?

Question Title

* 9. When selecting antifungal prophylaxis, I consider the local epidemiology when choosing the agent?

Question Title

* 10. The most common antifungal agent used for prophylaxis at your institution is:

Treatment

Question Title

* 11. At your institution, how often is combination antifungal therapy used for empiric treatment of invasive fungal infections?

Question Title

* 12. How often do you utilize IDSA guidelines when selecting treatment for candidiasis or aspergillosis?

Question Title

* 13. Which of the following present significant challenges to you when treating an IFI? (check all that apply)

T